Cart
sales@molnova.com
Nimucitinib
CAS No. 2740557-24-6
Nimucitinib( —— )
Catalog No. M36068 CAS No. 2740557-24-6
Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 147 | Get Quote |
|
| 5MG | 227 | Get Quote |
|
| 10MG | 353 | Get Quote |
|
| 25MG | 633 | Get Quote |
|
| 50MG | 908 | Get Quote |
|
| 100MG | 1377 | Get Quote |
|
| 500MG | 2673 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNimucitinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionNimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.
-
DescriptionNimucitinib is a Janus kinase (JAK) inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2740557-24-6
-
Formula Weight480.51
-
Molecular FormulaC25H26F2N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (260.14 mM; Ultrasonic )
-
SMILESN(CC1=CC(F)=CC(F)=C1)C=2C(C(N)=O)=CN=C(NC3=CC(NC(=O)[C@H]4CCCNC4)=CC=C3)C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WHO Drug Information, Vol. 36, No. 4, 2022.
molnova catalog
related products
-
WYE-151650
WYE-151650 is a novel potent, selective JAK3 inhibitor with IC50 of 0.8 nM, displays 36-, 14-, and 34-fold selectivity against JAK-1, JAK-2, and Tyk-2, respectively.
-
Levofloxacin
Levofloxacin is a broad-spectrum antibiotic topoisomerase II and topoisomerase IV inhibitor, used to treat respiratory, urinary tract, gastrointestinal, and abdominal infections.
-
BD750
BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in mouse and human T cells, respectively).
